Related Experiment Video
Updated: Aug 5, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Redefining the Landscape: Acquired Mutations Driving Systemic Autoinflammatory Diseases
Dorota Rowczenio1, Ebun Omoyinmi1,2, Jake Brown1
1National Amyloidosis Centre, Division of Infection, Immunity, and Rare Diseases, Royal Free London NHS Foundation Trust, London, United Kingdom.
Objective:
Mosaicism is a recognized cause of systemic autoinflammatory diseases (SAIDs). Initially described in cryopyrin-associated periodic syndromes (CAPS), it has since been reported in several dominantly inherited SAIDs, including Blau syndrome, tumor necrosis factor receptor-associated periodic syndrome (TRAPS), stimulator of interferon genes-associated vasculopathy with onset in infancy, NLRC4 inflammasomopathies, and familial Mediterranean fever. Recently, somatic variants underlying vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS syndrome) have extended this to late-onset disease. This study aimed to characterize the prevalence, spectrum, and clinical significance of acquired variants in SAIDs.
Methods:
A total of 5,530 patients referred to a national SAIDs reference center between 2017 and 2025 underwent deep next-generation sequencing autoinflammatory gene panel testing to detect low-level mosaicism. Results underwent multidisciplinary review and correlation with clinical data from electronic medical records.
Results:
SAID diagnoses were made in 403 of 5,530 patients (7.3%, 95% confidence interval [CI] 6.6%-8.0%). Among these, mosaic variants were identified in 83 patients (20.6%, 95% CI 16.9%-24.8%), including patients with VEXAS syndrome (69%), CAPS (24%), TRAPS (5%), Blau syndrome (1%), and NLRC4 inflammasomopathies (1%). Twenty-three distinct mosaic variants were identified across different SAIDs genes; in eight, the minor allele frequency was ≤5%. We report the first case of vertical transmission of TRAPS due to gonosomal mosaicism. AA amyloidosis complicated the disease course in 20% of patients diagnosed with late-onset mosaic CAPS.
Conclusion:
Somatic mosaicism is a frequent mechanism underlying late-onset SAIDs, which are often diagnosed late and carry a high risk of AA amyloidosis. To our knowledge, this represents the largest genetically heterogeneous single-center cohort of individuals with mosaic SAIDs reported to date.
Related Concept Videos
Inflammatory Bowel Disease III: Crohn's Disease
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Chronic Inflammation: Introduction
The JAK-STAT Signaling Pathway
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Inflammatory Bowel Disease II: Ulcerative Colitis